Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis

Table 1

Nodule sizes were measured in mice lungs 30 weeks after cell administration (LAM/TSC cells) and following anti-EGFR antibody or rapamycin treatment.

	LAM/TSC cells	Anti-EGFR antibody	Rapamycin
Average are of nodule size (µm^2)	10.337,228 ± 1.469	6.291,569 ± 807,1^*	4.822,547 ± 743,4^*

Data are expressed as mean ± SEM. versus mice 30 weeks after cell administration.